The xF+ Liquid Biopsy Panel by Tempus is specifically designed for the analysis of circulating tumor DNA (ctDNA) in solid tumor applications. By employing next-generation sequencing techniques, this panel offers an extensive coverage of regions that are pivotal in monitoring disease progression and treatment response. This non-invasive test is crucial for patients where traditional tissue biopsies may be impractical.
The panel includes robust analytical capabilities that provide oncologists with valuable data on genetic mutations critical to treatment planning. With deep sequencing coverages and sophisticated genomic insights, xF+ is instrumental in navigating complex oncology cases, especially for its precision in pinpointing clinically relevant alterations that influence treatment choices.
Featuring a unique methodology that emphasizes sensitivity and specificity, the xF+ Liquid Biopsy Panel plays an essential role in ongoing patient management. Its capability to analyze ctDNA provides critical insights into tumor dynamics over time, assisting healthcare professionals in evaluating therapy effectiveness and potential genomic mutations that could predict disease recurrence or progression.
